Stem Cell-Like Glioma Cells in Angiogenesis

血管生成中的干细胞样神经胶质瘤细胞

• 批准号: 8020967
• 负责人: JEREMY N RICH
• 金额: $ 31.6万
• 依托单位: CLEVELAND CLINIC LERNER COM-CWRU
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-04-07 至 2012-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8020967
• 关键词: Angiogenic Factor; Animal Model; Animals; Attenuated; Automobile Driving; Avastin; Behavior; Biological; Biological Markers; Biology; Biopsy Specimen; Blood Vessels; Brain Neoplasms; Cell Fraction; Cell Maintenance; Cell Survival; Cells; Characteristics; Clinical; Clinical Trials; Cytotoxic Chemotherapy; DNA damage checkpoint; Data; Development; Endothelial Cells; Foundations; Genes; Genetic Transcription; Glioblastoma; Glioma; Growth; Health; Human; Hypoxia; Hypoxia Inducible Factor; In Vitro; Laboratories; Link; Malignant Neoplasms; Mediating; Mediator of activation protein; Molecular; Operative Surgical Procedures; Outcome; Patients; Phase II Clinical Trials; Platelet Factor 4; Proteins; RNA Interference; Radiation; Radiation therapy; Recurrence; Relative (related person); Reporting; Resistance; Role; Specimen; Stem cells; Therapeutic; Toxic effect; Tumor Angiogenesis; Tumor Vascular Invasion; Vascular Endothelial Growth Factors; Work; Xenograft procedure; angiogenesis; antiangiogenesis therapy; bevacizumab; c-myc Genes; cancer cell; cancer stem cell; cell behavior; chemotherapy; conventional therapy; design; hypoxia inducible factor 1; improved; in vivo; insight; irinotecan; method development; nerve stem cell; neutralizing antibody; novel; novel therapeutic intervention; palliative; protein expression; radiation resistance; research study; response; self-renewal; stem; stem cell biology; stem cell therapy; success; therapy resistant; transcription factor; tumor; tumor growth; tumorigenesis; tumorigenic

DESCRIPTION (provided by applicant): Glioblastomas are highly lethal cancers for which conventional therapies are essentially palliative. We recently demonstrated that a subset of glioblastoma cells that share characteristics with somatic neural stem cells, cancer stem cells, are resistant to radiation and highly angiogenic. In combination with data from other laboratories, our results suggest that cancer stem cells are important determinants of the overall behavior of glioblastomas and that cancer stem cell directed therapies may be effective in controlling glioblastoma growth. Anti- angiogenic therapies may function as anti-stem cell therapies not only through the disruption of cancer stem cell angiogenesis but may also disrupt the vascular niche promoting cancer stem cell maintenance. This approach has direct therapeutic relevance as Bevacizumab (Avastin), a VEGF neutralizing antibody, has demonstrated activity in clinical trials for glioblastoma patients supporting potential utility of anti-angiogenic therapies for brain tumors. Critical to the success of anti-cancer stem cell approaches will be the limitation of toxicity to normal stem cells. Cancer cells reside in relative hypoxia, which has been linked to tumor angiogenesis, invasion, and resistance to therapy. Hypoxia increases stem cell maintenance suggesting that effects of hypoxia on cancer stem cells may contribute to tumor malignancy. To investigate the role of tumor vasculature in cancer stem cell biology and lay the foundation for potential new therapeutic approaches, we propose to: 1) Interrogate the response of cancer stem cells to hypoxia in survival, secretion of angiogenic factors, and invasion. 2) Determine the molecular mechanisms driving cancer stem cell specific responses to hypoxia relative to normal neural stem cells. 3) Determine if cancer stem cells provide a biomarker for patient response to bevacizumab therapy. The successful completion of these studies will better define the role of cancer stem cells in glioblastoma biology and provide direct therapeutic benefit. 4) Determine if targeting cancer stem cell hypoxic responses sensitizes tumors to cytotoxic therapies (radiotherapy, chemotherapy). PUBLIC HEALTH RELAVANCE: The cancer stem cell hypothesis may offer novel insights into glioblastoma angiogenesis and radiation resistance. We now seek to build on our prior studies of glioblastoma stem cells to understand the mechanisms by which these cells display preferential angiogenesis and survival upon treatment with radiation and chemotherapy. These studies may permit the selective targeting of cancer stem cells to improve tumor response to therapy.

描述（由申请人提供）：胶质母细胞瘤是一种高致死性癌症，常规治疗基本上是姑息性的。 我们最近证明，胶质母细胞瘤细胞的一个子集，与体细胞神经干细胞，癌症干细胞，具有抗辐射和高度血管生成的特征。 结合其他实验室的数据，我们的研究结果表明，癌症干细胞是胶质母细胞瘤整体行为的重要决定因素，癌症干细胞定向治疗可能有效控制胶质母细胞瘤生长。 抗血管生成疗法可作为抗干细胞疗法起作用，不仅通过破坏癌症干细胞血管生成，而且还可破坏促进癌症干细胞维持的血管生态位。 这种方法具有直接的治疗相关性，因为贝伐单抗（Avastin），一种VEGF中和抗体，已在胶质母细胞瘤患者的临床试验中证明了活性，支持抗血管生成疗法对脑肿瘤的潜在效用。 抗癌干细胞方法成功的关键是限制对正常干细胞的毒性。 癌细胞存在于相对缺氧中，这与肿瘤血管生成、侵袭和对治疗的抗性有关。 缺氧增加干细胞的维持，表明缺氧对癌症干细胞的影响可能有助于肿瘤恶性。为了研究肿瘤血管系统在肿瘤干细胞生物学中的作用，并为潜在的新治疗方法奠定基础，我们提出：1）询问肿瘤干细胞对缺氧的存活、血管生成因子的分泌和侵袭的反应。 2)确定驱动癌症干细胞相对于正常神经干细胞对缺氧的特异性反应的分子机制。 3)确定癌症干细胞是否为患者对贝伐单抗治疗的反应提供生物标志物。 这些研究的成功完成将更好地定义癌症干细胞在胶质母细胞瘤生物学中的作用，并提供直接的治疗益处。 4)确定靶向癌症干细胞缺氧反应是否使肿瘤对细胞毒性治疗（放疗，化疗）敏感。公共卫生关系：癌症干细胞假说可能为胶质母细胞瘤血管生成和辐射抗性提供新的见解。 我们现在寻求建立在我们以前的胶质母细胞瘤干细胞的研究，以了解这些细胞显示优先血管生成和生存的放射和化疗治疗后的机制。 这些研究可能允许选择性靶向癌症干细胞，以改善肿瘤对治疗的反应。